Know Cancer

or
forgot password

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging


The investigators are testing the effectiveness of an experimental imaging technology known
as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment
(shrinkage of tumor).

Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner.
This bedside-capable system combines frequency-domain photon migration with steady-state
tissue spectroscopy to measure complete(broadband) near-infrared absorption and reduced
scattering spectra of breast tissue in vivo. DOSI measurements are made by placing the
hand-held probe on the tissue surface and moving the probe to discrete locations along a
grid pattern at 1.0 cm intervals. The portable high-bandwidth Frequency-Domain Photon
Migration instrument employs intensity-modulated diode lasers and conventional steady-state
lamps as sources and an avalanche photodiode as the detector. The time required to perform
an Frequency-Domain Photon Migration measurement depends on the desired precision and number
of sweeps.


Inclusion Criteria:



- Female, 18 years of age or older, non pregnant or nursing.

- Diagnosis of breast cancer and will be receiving chemo therapy treatments

Exclusion Criteria:

- 18 years of age or younger, pregnant or nursing.

- Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.

- Previous diagnosis with other form of cancer.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response

Outcome Time Frame:

up to 12 months

Safety Issue:

No

Principal Investigator

Bruce Tromberg, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Laser Institute

Authority:

United States: Institutional Review Board

Study ID:

NIH/NCRR P41-RR01192

NCT ID:

NCT01257932

Start Date:

December 2010

Completion Date:

December 2015

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • Breast Neoplasms

Name

Location

Beckman Laser InstituteIrvine, California  92612